29. Oxybutynin (Ditropan) is prescribed for a client diagnosed with an overactive bladder (OAB).

29. Oxybutynin (Ditropan) is prescribed for a client diagnosed with an overactive bladder (OAB). The client reports having experienced numerous adverse effects with the immediate-release tablets (Ditropan-IR). The client asks the nurse how the transdermal patch could cause less adverse effects if it is essentially the same drug. The nurse’s response should be based on the knowledge : a. Transdermal absorption bypasses metabolism in the intestinal wall. b. The transdermal form is water soluble and poorly absorbed. c. The transdermal form is a different drug than oral oxybutynin. d. The transdermal form is less effective than the extended-release (ER) oral form. 30. Poisoning by reversible cholinesterase inhibitors can be treated by administration of what drug? What is the action of this drug that reverses the symptoms?